Company intelligence / Profile preview

Zyngenia, Inc.

Gaithersburg, Maryland, United Stateszyngenia.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Zyngenia developed a proprietary platform to engineer single-molecule, multi-specific monoclonal antibody-based therapeutics (“Zybodies™”) capable of simultaneously targeting multiple disease pathways. The company advanced three programs into preclinical development and achieved proof-of-concept with both bi-specific and tri-specific candidates in cancer and inflammation. No clinical-stage assets or results have been reported publicly.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)Multi-specific antibodiesAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

2 assets

adalimumab-based Zybody

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Zyngenia, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zyngenia, Inc..

Explore the full profile